Researchers have launched two studies into identifying the common genetic factors among patients living with dry age-related macular degeneration (AMD) that could involve collection of data through optical practices.
Gyroscope Therapeutics has encouraged people living with late stage dry AMD to donate a saliva sample that would be genetically tested in order to better understand this cause of sight loss and inform the development of new therapies.
Charlotte Arnold, vice president of corporate affairs at Gyroscope Therapeutics, told Optician: ‘Scope and Telescope are both part of Gyroscope’s large-scale research effort to genotype more than 6,000 people with geographic atrophy secondary to dry AMD.’
Register now to continue reading
Thank you for visiting Optician Online. Register now to access up to 10 news and opinion articles a month.
Register
Already have an account? Sign in here
